The therapeutic potential of mTOR inhibitors in breast cancer

Rapamycin and modified rapamycins (rapalogs) have been used to prevent allograft rejection after organ transplant for over 15 years. The mechanistic target of rapamycin (mTOR) has been determined to be a key component of the mTORC1 complex which consists of the serine/threonine kinase TOR and at lea...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Clin Pharmacol
Asıl Yazarlar: Steelman, Linda S., Martelli, Alberto M., Cocco, Lucio, Libra, Massimo, Nicoletti, Ferdinando, Abrams, Stephen L., McCubrey, James A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2016
Konular:
Review‐themed Issue
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5061784/
https://ncbi.nlm.nih.gov/pubmed/27059645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12958
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller